Novo to track generic surge as semaglutide goes off patent

Patent Expiry Sparks Generic Rush in India

Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs like Wegovy and Ozempic, is bracing for a wave of generic semaglutide entries as the drug's main patent expires in India on March 20, 2026.

This development opens the door for over 50 domestic manufacturers to launch their own branded versions of the GLP-1 receptor agonist, which has revolutionized treatments for type 2 diabetes and obesity.

Industry experts anticipate these generics will slash prices significantly, potentially halving costs for patients compared to the original branded products.

For instance, one company is already rolling out a version priced at around 220 rupees per shot, with pen devices expected soon at monthly costs between 4,000 and 4,500 rupees depending on dosage.

This influx could transform access to weight management therapies in a country where obesity rates are climbing rapidly, making effective treatments more affordable for millions.

Novo's Strategic Moves to Counter Competition

In a timely response, Novo Nordisk secured US FDA approval for Wegovy HD, a higher-dose version containing 7.2 milligrams of semaglutide—triple the standard 2.4 milligram dose—just before the Indian patent cliff.

The approval, granted on March 19, 2026, under a fast-track program for national health priorities, positions the company to launch in the US this April.

This new formulation promises even greater weight loss, around 21 percent, giving Novo a buffer against generics that aren't yet equipped to match it.

The company has also cut prices on existing Wegovy doses in India by up to 37 percent last November and partnered with local firm Emcure for another semaglutide brand.

Meanwhile, Wegovy HD is already cleared in the European Union and UK, with single-dose pen approvals eyed for later this year.

These steps reflect Novo's multi-pronged defense in the fiercely competitive anti-obesity market.

Global Patent Landscape and Future Outlook

While India leads the generic surge, semaglutide patents remain robust in major markets like the US and Europe until the early 2030s, covering not just the active ingredient but also formulations, devices, and delivery methods.

"Earlier this year, we launched the Wegovy pill, and with the accelerated approval of Wegovy HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%. At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy HD to help even more people reach their weight and health goals."

Companies like Dr Reddy's plan aggressive expansions, targeting 87 countries in 2026 starting with Canada, Brazil, Turkey, and others, expecting substantial sales from their generic Wegovy versions.

Fellow Indian players such as Cipla, Lupin, Biocon, and Sun Pharma are also gearing up, alongside launches in China and South Africa.

These countries represent about 40 percent of the global population and a third of adults with obesity, potentially reshaping the market dynamics.

Novo isn't standing still; it may enhance services, offer rebates, or shift patients to patent-protected alternatives like oral semaglutide or newer therapies.

As competition intensifies, patients stand to benefit from lower costs and broader access, though innovators will push boundaries with superior options.

In summary, Novo Nordisk is closely tracking the generic semaglutide boom post-India patent expiry, countering with higher-dose Wegovy HD and price strategies amid a global shift promising cheaper obesity and diabetes treatments while patents hold firm in key Western markets.